<DOC>
	<DOCNO>NCT02301624</DOCNO>
	<brief_summary>To evaluate safety efficacy eculizumab treatment refractory gMG extension trial subject participate ECU-MG-301 trial .</brief_summary>
	<brief_title>ECU-MG-302 : An Extension Trial ECU-MG-301 Evaluate Safety Efficacy Eculizumab Refractory Generalized Myasthenia Gravis</brief_title>
	<detailed_description>Trial ECU-MG-301 , phase III clinical trial , initiate evaluate safety efficacy eculizumab treatment refractory gMG . This extension trial design provide subject participate ECU-MG-301 trial opportunity receive eculizumab collect clinical data provide long term safety efficacy information eculizumab subject refractory gMG .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>1 . Subject complete ECUMG301 trial . 2 . Subject give write informed consent . 3 . Subject willing able comply protocol requirement duration trial . 4 . Female subject childbearing potential must negative pregnancy test ( serum human chorionic gonadotropin [ HCG ] ) . All subject must practice effective , reliable medically approve contraceptive regimen trial 5 month follow discontinuation treatment . 1 . Subjects withdraw ECUMG301 trial result AE related trial drug . 2 . Female subject pregnant , breastfeed intend conceive course trial . 3 . Any medical condition circumstance , opinion Investigator , might interfere subject 's participation trial , pose add risk subject , confound assessment subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>gMG</keyword>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>